The largest U.S. banks are scrutinizing members of the Federal Reserve for any insight into how the central bank will tinker interest rates.Banksread more
Facebook's cryptocurrency project has already been met with skepticism from policymakers around the world.Technologyread more
The U.S. and China restarted their trade talks, but signs are showing a comprehensive deal could be a long way off, if it happens at all.Marketsread more
Stone, 66, a notorious Republican political operative who has described himself as a "dirty trickster," had previously been dressed down by the judge for his public remarks...Politicsread more
The Biden team's second-quarter Federal Election Commission filing shows that the campaign wrote a check of just over $5,300 on June 28 to Sheehan Associates for "strategic...2020 Electionsread more
See which stocks are posting big moves after the bell on July 16.Market Insiderread more
While the vote served as a show of solidarity for Democrats, it recommended no substantive penalty against Trump.Politicsread more
United Airlines' second-quarter profit tops estimates but questions about the 737 Max linger.Airlinesread more
Three civil rights groups filed a federal lawsuit on Tuesday challenging the Trump administration's new asylum rule, which bars asylum claims from most noncitizens who travel...Politicsread more
Google VP of policy Karan Bhatia started sweating early as hearing chair Ted Cruz brings out an internal presentation created within the company.Technologyread more
At a hearing with the House Judiciary subcommittee on antitrust, an Amazon representative disputed a key argument about how it users sellers' data.Technologyread more
Shares of Canadian pot grower Tilray fell sharply on Monday, erasing gains from a wild week that captivated investors everywhere.
The stock tanked 19.1 percent. Last week, Tilray's stock posted a 12.8 percent gain after some sharp moves.
Tilray's stock surged more than 77 percent in the first three trading days of last week but then dropped 47.9 percent to close out the week. The initial jump sent Tilray's market cap to nearly $20 billion before ending the week around $10 billion.
Two catalysts drove Tilray's initial surge last week. First, Tilray announced on Tuesday the Drug Enforcement Administration approved it to import marijuana to the U.S. for medical research. CEO Brendan Kennedy later told CNBC's that global pharmaceuticals must think about partnering with cannabis producers as a "hedge" against the space.
"Cannabis is a substitute for prescription painkillers, prescription opioids, and so if you're an investor in a pharmaceutical company or you're a pharmaceutical company, you have to hedge the offset from cannabis substitution," Kennedy said.
Tilray's meteoric rise also bolstered other marijuana stocks. The ETFMG Alternative Harvest ETF (MJ), which tracks marijuana shares, rose more than 10 percent last week. Shares of Toronto-listed Cronos Group, meanwhile, gained 18.3 percent, while Aurora Cannabis jumped 38 percent.